Literature DB >> 3632394

Prednisone treatment in Duchenne muscular dystrophy. Long-term benefit.

S DeSilva, D B Drachman, D Mellits, R W Kuncl.   

Abstract

We report the long-term results of a therapeutic trial of prednisone in the treatment of Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate. Survival curve analysis and group mean comparisons indicate that ambulation was significantly prolonged, by approximately two years, in the prednisone-treated group compared with the control group. The results of this study indicate that prednisone therapy has a long-term beneficial effect in the treatment of Duchenne muscular dystrophy, in addition to the short-term palliation we previously reported. Further studies are needed to establish optimal treatment schedules using prednisone and to develop improved therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3632394     DOI: 10.1001/archneur.1987.00520200022012

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  29 in total

1.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.

Authors:  Luca Bello; Heather Gordish-Dressman; Lauren P Morgenroth; Erik K Henricson; Tina Duong; Eric P Hoffman; Avital Cnaan; Craig M McDonald
Journal:  Neurology       Date:  2015-08-26       Impact factor: 9.910

2.  The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies.

Authors:  Mahmoud R Hussein; Sherifa A Hamed; Mohammed G Mostafa; Eman E Abu-Dief; Nageh Fouly Kamel; Mahmoud R Kandil
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

Review 3.  The muscular dystrophies: from genes to therapies.

Authors:  Richard M Lovering; Neil C Porter; Robert J Bloch
Journal:  Phys Ther       Date:  2005-12

4.  Mineralocorticoid receptors are present in skeletal muscle and represent a potential therapeutic target.

Authors:  Jessica A Chadwick; J Spencer Hauck; Jeovanna Lowe; Jeremiah J Shaw; Denis C Guttridge; Celso E Gomez-Sanchez; Elise P Gomez-Sanchez; Jill A Rafael-Fortney
Journal:  FASEB J       Date:  2015-07-15       Impact factor: 5.191

5.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.

Authors:  Yetrib Hathout; Ramya L Marathi; Sree Rayavarapu; Aiping Zhang; Kristy J Brown; Haeri Seol; Heather Gordish-Dressman; Sebahattin Cirak; Luca Bello; Kanneboyina Nagaraju; Terry Partridge; Eric P Hoffman; Shin'ichi Takeda; Jean K Mah; Erik Henricson; Craig McDonald
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

6.  Identification of small molecule and genetic modulators of AON-induced dystrophin exon skipping by high-throughput screening.

Authors:  Debra A O'Leary; Orzala Sharif; Paul Anderson; Buu Tu; Genevieve Welch; Yingyao Zhou; Jeremy S Caldwell; Ingo H Engels; Achim Brinker
Journal:  PLoS One       Date:  2009-12-17       Impact factor: 3.240

7.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

8.  Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Authors:  Wenwei Shao; Xiaojing Chen; Richard J Samulski; Matthew L Hirsch; Chengwen Li
Journal:  Hum Mol Genet       Date:  2018-02-15       Impact factor: 6.150

9.  Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment.

Authors:  H Kawai; K Adachi; Y Nishida; T Inui; C Kimura; S Saito
Journal:  J Neurol       Date:  1993       Impact factor: 4.849

10.  Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.

Authors:  Hee Kyung Kim; Tal Laor; Paul S Horn; Brenda Wong
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.